M
Marc Damelin
Researcher at Pfizer
Publications - 32
Citations - 1473
Marc Damelin is an academic researcher from Pfizer. The author has contributed to research in topics: Antibody-drug conjugate & Cancer. The author has an hindex of 9, co-authored 28 publications receiving 1270 citations.
Papers
More filters
Journal ArticleDOI
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Bin-Bing S. Zhou,Haiying Zhang,Marc Damelin,Kenneth G. Geles,Justin C. Grindley,Peter B. Dirks +5 more
TL;DR: This Review considers recent advances in the cancer stem cell field, focusing on the challenges and opportunities for anticancer drug discovery.
Journal ArticleDOI
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
Marc Damelin,Alexander J. Bankovich,Jeffrey Bernstein,Justin Lucas,Liang Chen,Samuel A. Williams,Albert Park,Jorge Aguilar,Elana Ernstoff,Manoj Charati,Russell Dushin,Monette Aujay,Christina R. Lee,Hanna Ramoth,Milly Milton,Johannes Hampl,Sasha Lazetic,Virginia Pulito,Edward Rosfjord,Yongliang Sun,Lindsay King,Frank Barletta,Alison Betts,Magali Guffroy,Hadi Falahatpisheh,Christopher J. O’Donnell,Robert A. Stull,Marybeth A. Pysz,Paul Anthony Escarpe,David R. Liu,Orit Foord,Hans-Peter Gerber,Puja Sapra,Scott J. Dylla +33 more
TL;DR: The authors demonstrated the effectiveness of this therapy in mouse models of several tumor types and confirmed that it reduces tumor-initiating cells and outperforms standard chemotherapy, and also had some unexpected benefits, reducing tumor angiogenesis and promoting antitumor immunity.
Journal ArticleDOI
Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Puja Sapra,Marc Damelin,John F. DiJoseph,Kimberly Ann Marquette,Kenneth G. Geles,Jonathan Golas,Maureen Dougher,Bitha Narayanan,Andreas Giannakou,Kiran Khandke,Russell Dushin,Elana Ernstoff,Judy Lucas,Mauricio Leal,George Hu,Christopher J. O’Donnell,Lioudmila Tchistiakova,Robert T. Abraham,Hans-Peter Gerber +18 more
TL;DR: In this article, an anti-5T4 ADC (A1mcMMAF) was developed by sulfydryl-based conjugation of the humanized A1 antibody to the tubulin inhibitor monomethylauristatin F via a maleimidocaproyl linker.
Journal ArticleDOI
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
TL;DR: The tumor and normal tissue expression profiles of the targets of ADCs currently in clinical development are surveyed, demonstrating a surprisingly broad range of expression profiles and the inability to formalize any optimal parameters for an ADC target.
Journal ArticleDOI
Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Marc Damelin,Kenneth G. Geles,Maximillian T. Follettie,Ping Yuan,Michelle Baxter,Jonathon Golas,John F. DiJoseph,Maha Karnoub,Shuguang Huang,Veronica Diesl,Carmen Behrens,Sung E. Choe,Carol Rios,Janet Gruzas,Latha Sridharan,Maureen Dougher,Arthur Kunz,Hamann Philip Ross,Deborah Evans,Douglas Armellino,Kiran Khandke,Kimberly Ann Marquette,Lioudmila Tchistiakova,Erwin R. Boghaert,Robert T. Abraham,Ignacio I. Wistuba,Bin-Bing S. Zhou +26 more
TL;DR: Despite heterogeneous expression of 5T4 in NSCLC patient-derived xenografts, treatment with an anti-5T4 antibody-drug conjugate resulted in complete and sustained tumor regression.